Plasma-Derived Therapy for Hemophilia in The Updated European Medicines Agency’s Union List
Deborah Hibbett, Senior Vice President, Head of Global Corporate Affairs and Sustainability, Plasma-Derived Therapies at Takeda, shared on LinkedIn:
”The updated European Medicines Agency’s Union List of Critical Medicines now includes a plasma-derived therapy for hemophilia patients with inhibitors.
This addition underscores that reliable, uninterrupted access to critical medicines – including this product and the other listed plasma-derived therapies – is essential for patients, families and healthcare systems.
Takeda celebrates this update as we are also committed to the bleeding disorders community and to creating value through sustainable, equitable access – including our renewed collaboration with the WFH Humanitarian Aid Program and the work highlighted in Takeda’s 2025 Access to Medicines Update.
Thank you to the healthcare community, patient advocates and partners who continue to advance security of supply and equity in care every day.”
Stay updated with Hemostasis Today.
-
Dec 18, 2025, 17:13Daria Camilli on EuroBloodNet and EHC Collaboration for Bleeding Disorders
-
Dec 18, 2025, 16:50Marie Cambot on Innovhem’s Quantification of The HbF/HbS Ratio for SCD
-
Dec 18, 2025, 16:26Yogesh Rathod on Hematological Issues and ICU
-
Dec 18, 2025, 16:09Carlos Doti: I’m Reminded Why ASH is Such a Powerful Close to The Year
-
Dec 18, 2025, 15:23Michael Hadley: Well-Timed ACC Statement Just Out in JACC Journals
-
Dec 18, 2025, 15:12Wolfgang Miesbach on Insights from Guy Young’s ASH2025 Session on Next-Generation Gene Therapy
-
Dec 18, 2025, 13:55Laurent Bertoletti: BAT-VTE is One of 7 Projects Funded Under the EFFECT Trial Call!
-
Dec 18, 2025, 13:34Alexandru Stieber Explores VEXAS Syndrome
-
Dec 18, 2025, 12:12Niraj Sharma: Can We Really Stop Anticoagulation After AF Ablation?